Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Efficacy and Safety Comparison of 4-week Treatment Periods of Two Doses [5 μg (2 Actuations of 2.5 μg) and 10 μg (2 Actuations of 5 μg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Tiotropium Inhalation Powder Capsule (18μg) Delivered by the HandiHaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Verified date | November 2023 |
Source | Boehringer Ingelheim |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Non-inferiority of lung function response to Tiotropium inhalation solution compared to Spiriva HandiHaler
Status | Completed |
Enrollment | 131 |
Est. completion date | April 29, 2004 |
Est. primary completion date | April 29, 2004 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion criteria: - All patients had to sign an informed consent consistent with International Conference of Harmonization-Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial, which includes medication washout and restrictions. - All patients had to have a diagnosis of chronic obstructive pulmonary disease. - Patients had to have relatively stable, moderate to severe airway obstruction with an forced expiratory volume in one second (FEV1) = 60% of predicted normal and FEV1 = 70% of forced vital capacity FVC (Visits 1 and 2). - Male or female patients 40 years of age or older. - Patients had to be current or ex-smokers with a smoking history of more than 10 pack-years. - Patients had to be able to perform technically acceptable pulmonary function tests and peak expiratory flow rate (PEFR) measurements, and had to be able to maintain records (Patient Daily Diary Card) during the study period as required in the protocol. - Patients had to be able to inhale medication in a competent manner from the Respimat inhaler, the HandiHaler and from a metered dose inhaler (MDI). Exclusion criteria: - Patients with significant diseases other than chronic obstructive pulmonary disease (COPD) had to be excluded. A significant disease was defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study. - Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis, if the abnormality defines a significant disease as defined in exclusion criterion No. 1. - Patients with a recent history (i.e., one year or less) of myocardial infarction. - Patients with any cardiac arrhythmia requiring drug therapy or who had been hospitalised for heart failure within the past three years. - Patients with a history of cancer within the last five years. Patients with treated basal cell carcinoma were allowed. - Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction. - Patients with known narrow-angle glaucoma. - Patients with a history of asthma, allergic rhinitis or who have a total blood eosinophil count =600 mm3. - Further exclusion criteria apply |
Country | Name | City | State |
---|---|---|---|
Canada | Montreal Chest Institute - McGill University Health Centre | Montreal | Quebec |
United States | National Jewish Medical and Research Center | Denver | Colorado |
United States | Division of Pulmonary and Critical Care Medicine | Little Rock | Arkansas |
United States | Minisota Lung Center | Minneapolis | Minnesota |
United States | Boehringer Ingelheim Investigational Site | San Diego | California |
United States | San Jose Clinical Research | San Jose | California |
United States | LSU MC-Sheveport | Shreveport | Louisiana |
United States | Spartanburg Medical Research | Spartanburg | South Carolina |
United States | Boehringer Ingelheim Investigational Site | Stockton | California |
United States | Boehringer Ingelheim Investigational Site | Tacoma | Washington |
United States | Wake Forest University School of Medicine | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Boehringer Ingelheim |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Trough FEV1 response determined at the end of each 4-week period of randomised treatment. | at the end of each 4-week period | ||
Secondary | Tiotropium plasma concentration data and urinary excretion data | at the end of each 4-week period | ||
Secondary | Trough forced vital capacity (FVC) response | after 4 weeks | ||
Secondary | Peak response (FEV1 and FVC) | within 3 hours after first dose, after 4 weeks | ||
Secondary | FEV1 AUC 0-12h and FVC AUC 0-12h response | after 4 weeks | ||
Secondary | FEV1 AUC 0-3h and FVC AUC 0-3h response | after the first dose, after 4 weeks | ||
Secondary | Individual FEV1and FVC measurements | during study course of 28 weeks | ||
Secondary | pre-dose morning and evening peak expiratory flow rate (PEFR) | during study course of 28 weeks | ||
Secondary | Number of occasions of rescue therapy used | during study course of 28 weeks | ||
Secondary | Median time to onset of therapeutic response after first dose (FEV1) | after first dose and after 4 weeks | ||
Secondary | Number of patients with 15% response above baseline for each treatment at each time point after first dose and after 4 weeks | up to 28 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|